Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most general statements about Fabior being tazarotene foam for acne, topical use, and common local irritation/photosensitivity are consistent with the label excerpts. However, some dosing/usage details and safety guidance are incomplete or not fully supported by the provided label (notably irritation severity wording, photosensitivity/sun sensitivity phrasing, and absence of contraception/pregnancy specificity).
Category Scores
Accurate Statements
Fabior is a brand of topical foam.
Section 2 (topical use only) and drug identity FABIOR (tazarotene) Foam 0.1%.
Fabior contains tazarotene.
Drug identity: FABIOR (tazarotene) Foam 0.1%.
Tazarotene is a retinoid.
Section 12.1 (tazarotene is a retinoid prodrug).
Fabior is used for skin conditions such as acne.
Section 1 indicates topical treatment of acne vulgaris.
Fabior is applied to affected areas according to the prescribing instructions.
Section 2 provides application instructions for affected areas.
Retinoids can irritate skin.
Section 5.2 (local irritation; redness/peeling/burning/excessive pruritus) and Section 6.1 (application site irritation, dryness, erythema, exfoliation).
Retinoids may increase sensitivity to sunlight.
Section 5.4 (photosensitivity; avoid sunlight; sunburn risk) and Section 6.1 includes application site photosensitivity including sunburn.
Common side effects associated with Fabior include irritation at or around the application site.
Section 6.1: application site irritation (14%).
Common side effects associated with Fabior include redness at or around the application site.
Section 6.1: application site erythema (6%).
Common side effects associated with Fabior include dryness at or around the application site.
Section 6.1: application site dryness (7%).
Fabior is a prescription medication.
Not explicitly present in the provided excerpts; however it is implied by “prescribing information.” (No direct label excerpt provided establishing prescription status.)
The product labeling should be followed for Fabior.
General alignment with Section 2 dosing/administration instructions (follow prescribing instructions).
Clinicians can advise on contraindications and safety for specific patient groups for Fabior.
Section 4 and Section 8 provide contraindications and specific-population cautions; label supports the concept of clinician guidance.
Fabior is one formulation/brand that uses tazarotene.
Drug identity: FABIOR (tazarotene) Foam 0.1%.
Other retinoid options may differ by formulation (cream/gel/foam).
No specific label statement about other retinoid products; partially general but not contradicted by provided excerpts.
Other retinoid options may differ by tolerability.
No specific label statement about other retinoid products; not contradicted by provided excerpts.
Fabior is a branded product containing tazarotene.
Drug identity.
Availability of generics for tazarotene depends on the market and specific formulation.
Not addressed in provided label excerpts.
Unsupported Statements
Fabior is a prescription medication.
No explicit statement about prescription-only status in the provided label excerpts.
Other retinoid options may differ by strength.
Not supported by provided FABIOR label excerpts.
Differences in strength, formulation, and tolerability can affect how easily retinoids spread.
Not supported by provided label excerpts.
Differences in strength, formulation, and tolerability can affect how much retinoids irritate.
Not supported by provided label excerpts.
Availability of generics for tazarotene depends on the market and specific formulation.
Not addressed in provided label excerpts.
Patients should stop using Fabior if irritation becomes severe.
Section 2 states to reduce frequency or temporarily interrupt for undue irritation and to discontinue if irritation persists, but it does not define or use the threshold wording “severe.”
Patients should contact a clinician if irritation becomes severe.
Section 2 does not include “contact a clinician” language or a severity threshold; label only specifies reducing frequency/interrupting and discontinuing if irritation persists, plus caution to avoid eyes/mucous membranes.
Contradictions
Important Omissions
Pregnancy contraindication and required pregnancy prevention measures for females of childbearing potential (e.g., contraception, timing of pregnancy test, discontinue if pregnancy occurs).
Importance:
High
Explicit labeling of contraindication: contraindicated in pregnancy and may cause fetal harm; discontinue if pregnancy occurs.
Importance:
High
Pediatric age limitation: safety/effectiveness not established in patients younger than 12 years.
Importance:
Moderate
Complete and specific administration instructions (once daily in the evening, after washing and fully drying, thin layer to face/upper trunk, avoid eyes/lips/mucous membranes, wash hands, moisturizer as needed).
Importance:
Moderate
Photosensitivity precautions beyond general “may increase sensitivity to sunlight,” including avoidance of sunlight/sunlamps and use of sunscreen/protective clothing; caution with history of skin cancer and photosensitizing drugs.
Importance:
Moderate
Flammability instruction: propellant is flammable; avoid fire/flame/smoking during and immediately following application.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-critical label elements were omitted or generalized, especially pregnancy contraindication/contraception and specific irritation management wording (“reduce frequency/interrupt; discontinue if persists”), plus lack of explicit flammability and detailed photosensitivity precautions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omitted or generalized high-importance safety information (pregnancy contraindication/contraception and specific label instructions for irritation management and photosensitivity/flammability).
Suggested Improvement
Include label-specific pregnancy contraindication and required contraception/pregnancy test guidance; replace “severe irritation” language with the label’s instructions (reduce frequency or temporarily interrupt; discontinue if irritation persists); add key administration and safety precautions (avoid eyes/mucous membranes, once-daily evening application after cleansing, sunscreen/protective clothing and sun avoidance, and flammability precautions).